Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 3/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28780875 | 0.79 | P2RX3 (0.54) | IKBKB | |
| SCHEMBL3217195 | 0.77 | BRD4 (0.50) | ALDH1A1KDM4EHPGDSMN1; SMN2USP2 | |
| SCHEMBL28790249 | 0.75 | PLA2G10 (0.45) | ALDH1A1HPGDUSP2MAPTALOX15 | |
| SCHEMBL28790250 | 0.75 | IKBKB (0.54) | ALDH1A1KDM4EHPGDSMN1; SMN2MAPT | |
| SCHEMBL27824628 | 0.74 | RCE1 (0.49) | ALDH1A1HPGDUSP2MAPTALOX15 | |
| SCHEMBL7257033 | 0.72 | ADAM17 (0.55) | ALDH1A1KDM4ESMN1; SMN2MAPTPLA2G10 | |
| SCHEMBL3946630 | 0.72 | ADORA2A (0.45) | ALDH1A1KDM4EHPGDSMN1; SMN2USP2 | |
| SCHEMBL13740601 | 0.72 | ADORA2A (0.48) | TLR7 | |
| SCHEMBL28790298 | 0.71 | KDM4E (0.47) | ALDH1A1KDM4EHPGDSMN1; SMN2MAPT | |
| SCHEMBL31295740 | 0.71 | POLB (0.67) | ALDH1A1KDM4EHPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101951771-A | Composition for agricultural use for controlling or preventing plant diseases caused by plant pathogens | SUMITOMO CHEMICAL CO | 2011-01-19 | — | — | CN | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| CN-101600715-A | Compound with angiotensin-ii receptor antagonistic action and PPAR γ activating activities | PFIZER PROD INC (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-2125806-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | Pfizer Products Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008084303-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | AGTR2, AGTR1, AGT | ALDH1A1 1739/4885KDM4E 4566/4885HPGD 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.